PCM
CSTL icon

Palisade Capital Management’s Castle Biosciences CSTL Stock Holding History

Palisade Capital Management’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$13.2M Sell
535,884
-31,893
-6% -$1.04M 0.44% 87
2025
Q4 		$22.1M Sell
567,777
-70,879
-11% -$2.29M 0.65% 59
2025
Q3 		$14.5M Buy
638,656
+63,540
+11% +$1.29M 0.4% 90
2025
Q2 		$11.7M Buy
575,116
+85,148
+17% +$1.58M 0.33% 97
2025
Q1 		$9.81M Sell
489,968
-13,474
-3% -$334K 0.28% 111
2024
Q4 		$13.4M Buy
503,442
+1,125
+0.2% +$34.3K 0.36% 96
2024
Q3 		$14.3M Sell
502,317
-35,657
-7% -$908K 0.38% 90
2024
Q2 		$11.7M Sell
537,974
-9,193
-2% -$205K 0.32% 101
2024
Q1 		$12.1M Buy
547,167
+8,032
+1% +$175K 0.32% 102
2023
Q4 		$11.6M Sell
539,135
-63,126
-10% -$1.11M 0.31% 103
2023
Q3 		$10.2M Buy
602,261
+57
+0% +$997 0.28% 107
2023
Q2 		$8.26M Buy
602,204
+25,186
+4% +$510K 0.22% 129
2023
Q1 		$13.1M Buy
577,018
+25,923
+5% +$633K 0.35% 96
2022
Q4 		$13M Sell
551,095
-28,849
-5% -$669K 0.35% 96
2022
Q3 		$15.1M Buy
579,944
+1,011
+0.2% +$28.3K 0.43% 78
2022
Q2 		$12.7M Buy
578,933
+169,701
+41% +$3.94M 0.34% 91
2022
Q1 		$18.4M Buy
409,232
+56,791
+16% +$2.35M 0.42% 80
2021
Q4 		$15.1M Buy
+352,441
New +$18.4M 0.31% 104

Other funds holding CSTL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
SPPAM
Summit Partners Public Asset Management Boston, Massachusetts $3.72B AUM 162.29% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Allianz Asset Management
Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Palisade Capital Management's CSTL Position: Q1 2026 in Review

Palisade Capital Management reduced its Castle Biosciences (CSTL) stake by 5.6% in Q1 2026, selling an estimated $1.04M and leaving 535,884 shares worth $13.2M. The position accounts for 0.44% of the portfolio, ranked #87.

Palisade Capital Management first reported a position in CSTL in Q4 2021 and has held it in 18 quarters since. The position peaked at $22.1M in Q4 2025. 186 funds tracked by Wall St. Rank hold CSTL as of Q1 2026.

  • Palisade Capital Management held 535,884 shares of Castle Biosciences worth $13.2M as of Q1 2026.
  • Palisade Capital Management sold 31,893 Castle Biosciences shares in Q1 2026, an estimated $1.04M.
  • Castle Biosciences made up 0.44% of Palisade Capital Management's portfolio in Q1 2026, its #87 holding.
  • Palisade Capital Management first reported a position in Castle Biosciences in Q4 2021 and has held it in 18 quarters since.
  • Palisade Capital Management's Castle Biosciences position peaked at $22.1M in Q4 2025.
  • 186 funds tracked by Wall St. Rank held Castle Biosciences as of Q1 2026.

Based on Palisade Capital Management's 13F filing for Q1 2026, filed 15 May 2026.